Navigation Links
Bionovo Announces Closing of Follow-on Offering of Common Stock and Warrants
Date:2/2/2011

EMERYVILLE, Calif., Feb. 2, 2011 /PRNewswire/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the closing of its previously announced underwritten public offering of 30,031,200 units at a price per unit of $1.00. Each unit consists of one share of common stock and a warrant to purchase one half of one share of Bionovo common stock at an exercise price of $1.30 per share.  The warrants may be exercised at any time after the date of the closing and will expire after five years.  

The net proceeds to the company from the sale of units in the offering, after deducting underwriting discounts and commissions and anticipated expenses of the offering, are expected to be $27.8 million. The financing was led by Roths-Invest Asset Management AG, from the Nathan Rothschild Group, Zurich, Switzerland. "Bionovo's approach to drug development is novel and promising," said Jan Sommerhalder, Head of Investments at Roths-Invest. "Menerba, as a targeted botanical drug, has the potential to address a large unmet medical need, providing menopausal women with a proven natural therapy that they have long awaited."

Bionovo expects to use the net proceeds from this offering to advance its lead drug candidate for postmenopausal vasomotor symptoms, Menerba, into Phase 3 clinical trials, and for general corporate purposes.

Dr. Isaac Cohen, chairman and chief executive officer of Bionovo, Inc. commented, "Having positive data to date, regulatory clarity, and now sufficient funding, we can confidently proceed in advancing Menerba into Phase 3 clinical trials. We believe Menerba has the ability to be an important new treatment approach for millions of women suffering from menopausal issues."

Cowen and Company, LLC, acted as the sole bookrunner for
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bionovo, Inc. to Announce First Quarter Fiscal Year 2010 Financial Results on Tuesday, May 11, 2010
2. Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer
3. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
4. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009
5. Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer
6. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
7. Bionovo Announces 2008 Highlights and Year-End Financial Results
8. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
9. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
10. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
11. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... /PRNewswire/ - bioLytical Laboratories Inc., a leader in rapid ... Sensitivity of a rapid point of care assay for ... for HIV gp41 IgM antibodies " has been published ... INSTI,s ability to detect early HIV infection.  ... th annual International AIDS Society Conference, which highlighted ...
(Date:9/3/2015)... ... 03, 2015 , ... If you plan to attend the 27th annual ... also want to sign up for the tour of Framingham State University's newest addition ... walk through of the (8) chemistry teaching labs that are exclusively utilizing (49) ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biochips and Microarrays ... offering. This report is an analysis ... The report starts with a description of technologies ... include array comparative genomic hybridization (CGH), copy number ...
(Date:9/2/2015)... Virginia , September 2, 2015 ... of the winners of the 2015 BeHEARD science challenge, ... that offers rare disease researchers, access to the latest ... use its drug repositioning and pathway analytics capability to ... Wylder Nation Foundation in the study of Niemann-Pick Disease ...
Breaking Biology Technology:bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2
... June 26 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... yesterday on its monoclonal antibody product, Angiolix(R), at,the ... Dublin,Ireland. Dr. Agamemnon Epenetos, Access, Chief Scientific Officer ... potential to prevent,the growth of cancer stem cells., ...
... Ill. Now you see it, soon you might ... In computer simulations, the researchers have demonstrated an approximate ... crystals. The mathematical proof brings scientists a step closer ... is much more than a theoretical exercise," said Harley ...
... felt a down economy at all. PHC Consulting is focused on ... clinical and research, physician call points, medical devices, pharmaceutical, etc). So ... that growth to a strong web presence. , ... ...
Cached Biology Technology:Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells 2Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells 3Silicon photonic crystals key to optical cloaking, researchers say 2Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point 2
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, Inc ... improving the user experience and security of consumer ... today announced that its TrulySecure™ is ... software to be FIDO Certified™. The ... compliance with the FIDO UAF (Universal Authentication Framework) ...
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
(Date:8/12/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is proud to announce that iMedNet ... technology platform, has led the way to significant and ... 2015.   Q2 2015 and Q1 2015 were, respectively, ... value sold in the company,s 15 year history.  In ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2
... few minutes looking at your child's eye color. ... for. According to Bruno Laeng and colleagues, from ... reflects a simple, predictable and reliable genetic pattern of ... Springer journal Behavioral Ecology and Sociobiology, show that blue-eyed ...
... that furthers our understanding of how hybridization may contribute ... researchers have found that the genomes of three sunflower ... same two parental types have undergone a massive proliferation ... are reported by Mark Ungerer and colleagues at Kansas ...
... mental activity and enhancing mental function can improve ... an effective addition to medications commonly used to ... computer activities were even more successful than classic ... patients. The findings, from the FundaciĆ³ ACE, Institut ...
Cached Biology News:Blue eyes -- A clue to paternity 2Sunflower speciation highlights roles for transposable elements in evolution 2Computer-based 'games' enhance mental function in patients with Alzheimer's 2
versican (H-56)...
... degrades single-stranded DNA and RNA endonucleolytically ... acids (DNA:DNA, DNA:RNA or RNA:RNA) are ... high concentrations of enzyme (1). The ... termini from double-stranded DNA (2), for ...
... catalyzes the transfer of the ... 5-terminus of polynucleotides or to ... The enzyme, purified from recombinant ... to phosphorylate RNA, DNA and ...
... verticillus USBio Analyzed PRODUCT SPECIFICATIONS Form: White powder Assay: 1.5 ... units/ml): 4.5 to 6.0 Loss On Drying: less than or ... 0.1% Bleomycin Content: A 2 : 55 - 70% B ... : greater than or equal to 90% B 4 : ...
Biology Products: